My friends, I’m just going to keep my investment in this one. It might be a great alternative to tech and AI stocks for you, too.
Investing.com - Shares of Swedish biopharmaceutical company Camurus AB rose more than 16% on Wednesday to their highest level since February after the company reported record second-quarter sales of its drug Buvidal, used to treat opioid addiction. The figures significantly exceeded analysts’ forecasts and ended a prolonged period of underperformance.
Camurus stock reached a high of 615 SEK during the trading day, its highest level since February 11, 2026, after the company announced total revenue of 702 million SEK for the second quarter of 2026, compared to a consensus estimate of 626 million SEK.
Product revenue from Buvidal reached a record high of 528 million SEK, surpassing the 500 million SEK mark for the first time. The consensus estimate was SEK 467 million. Operating profit for the second quarter amounted to SEK 293 million, compared with a consensus of SEK 238 million.
Analysts at Stifel, who rate the stock “Buy” with a price target of 780 SEK, described the results as “exceeding expectations across the board.” Buvidal’s performance signals “a solid recovery from recent quarters.” Growth was supported by a net increase of 4,000 patients on treatment and improved sales figures in the United Kingdom, where new National Health Service funding is taking effect.
The operating margin for the quarter reached 42%. Royalty revenue from net sales of Brixadi—the U.S. brand name for Buvidal—generated by U.S. partner Braeburn rose 42% year-over-year to SEK 127 million.
